Pro-apoptotic peptides-based cancer therapies: challenges and strategies to enhance therapeutic efficacy

Arch Pharm Res. 2018 Jun;41(6):594-616. doi: 10.1007/s12272-018-1038-y. Epub 2018 May 26.

Abstract

Cancer is a leading cause of death worldwide. Despite many advances in the field of cancer therapy, an effective cure is yet to be found. As a more potent alternative for the conventional small molecule anti-cancer drugs, pro-apoptotic peptides have emerged as a new class of anticancer agents. By interaction with certain members in the apoptotic pathways, they could effectively kill tumor cells. However, there remain bottleneck challenges for clinical application of these pro-apoptotic peptides in cancer therapy. In this review, we will overview the developed pro-apoptotic peptides and outline the widely adopted molecular-based and nanoparticle-based strategies to enhance their anti-tumor effects.

Keywords: Anti-cancer drugs; Cancer; Molecular approaches; Nanoparticles; Pro-apoptotic peptides.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / pharmacology*
  • Antineoplastic Agents / therapeutic use
  • Apoptosis / drug effects*
  • Apoptosis Regulatory Proteins / agonists
  • Apoptosis Regulatory Proteins / antagonists & inhibitors
  • Apoptosis Regulatory Proteins / metabolism
  • Drug Delivery Systems / methods
  • Drug Design
  • Humans
  • Molecular Targeted Therapy / methods*
  • Molecular Targeted Therapy / trends
  • Nanoparticles / chemistry
  • Neoplasms / drug therapy*
  • Peptides / pharmacology*
  • Peptides / therapeutic use
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Apoptosis Regulatory Proteins
  • Peptides